Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSC-DC vaccine (Fuda Cancer Hospital)
- Development stage
- Unknown
- Lead developer
- Fuda Cancer Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
CSC-DC is an autologous dendritic cell vaccine loaded with cancer stem cell (CSC) antigens, developed by Fuda Cancer Hospital in Guangzhou. The vaccine is designed to target the CSC population, which is often resistant to conventional chemotherapy and responsible for tumor recurrence and metastasis. By pulsing dendritic cells with CSC-enriched antigens, the therapy aims to prime the immune system—specifically cytotoxic T lymphocytes (CTLs) and B cells—to recognize and eliminate CSCs. In clinical studies, it has been evaluated for safety and immunogenicity in patients with stage III epithelial ovarian cancer in remission or metastatic ovarian adenocarcinoma.
- Other names
- Cancer Stem Cell-loaded Dendritic Cell vaccineCSC-DC Vaccine
02
Targets
CCR10 (C-C chemokine receptor type 10)Cancer stem cell antigens derived from aldehyde dehydrogenase-high cancer stem cell lysates
Beyond the preview
Go deeper on CSC-DC vaccine (Fuda Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSC-DC vaccine (Fuda Cancer Hospital).